NeoVolta Appoints Michael Mendik as Chief Operating Officer
Get Alerts NEOV Hot Sheet
Join SI Premium – FREE
"We are thrilled to welcome
In his new role as COO, Michael will oversee NeoVolta's operations, including sales, marketing, product management, and customer service. He will be responsible for driving operational efficiencies, enhancing customer experience, and leading the company's growth initiatives.
Michael holds a PhD in Natural Sciences and a master's degree in Physics from the Swiss Federal Institute of Technology,
About NeoVolta
NeoVolta is dedicated to providing reliable, sustainable, and high-performance energy storage systems. With a focus on cutting-edge technology and strategic partnerships, NeoVolta is committed to driving progress in renewable energy and enhancing how the world stores and uses power.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neovolta-appoints-michael-mendik-as-chief-operating-officer-302343773.html
SOURCE NeoVolta
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Muscle Growth Supplements Featuring Magnesium, Ashwagandha and Omega-3s Are Highlighted by PureHealth Research
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share